You just read:

Blueprint Medicines to Present Proof-of-Concept Data from Ongoing Phase 1 Clinical Trial of BLU-667 in Patients with RET-Altered Solid Tumors in a Clinical Trials Plenary Session at AACR Annual Meeting 2018

News provided by

Blueprint Medicines Corporation

Mar 14, 2018, 16:35 ET